Upgrade to SI Premium - Free Trial

BofA/Merrill Lynch Downgrades GlaxoSmithKline (GSK) to Neutral

October 26, 2017 4:42 AM
BofA/Merrill Lynch downgraded GlaxoSmithKline (NYSE: GSK) from Buy to Neutral.Analyst Graham Parry says the valuation is not demanding and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades

Next Articles